Kuang, M., Tan, L., Xu, L., Shen, S., Li, D., Hua, Y., Li, S., Liang, L., He, Q., Zhou, Q., Xie, W., Chen, Z., Wu, J., Li, J., Fan, W., Zhuang, W., Chen, L., Feng, S., Peng, S., Wang, J. (2025). Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e16304